posted on 12/30/2020 17:21 / updated on 12/30/2020 6:06 pm
A week ago, the United Kingdom had announced approval of the vaccine produced by the Astrazeneca laboratory in partnership with the University of Oxford – (credit: AFP PHOTO / UNIVERSITY OF OXFORD / John Cairns)
The regulatory agency for medicines and food in Argentina (Anmat), equivalent to Anvisa, has just approved the emergency use of the vaccine produced by the laboratory AstraZeneca, in partnership with the University of Oxford, against covid-19. The announcement was made this Wednesday afternoon (12/30) in a press release sent by the agency.
“The said product has an acceptable risk-benefit ratio, allowing to subsidize the registration grant and the conditional authorization of the product for the requested indication. It was granted for a period of one year from the date of this provision, under the condition of sale under prescription ”, says the document according to the local newspaper La Nación.
A week ago, the agency in the neighboring country had already authorized the emergency use of the immunizer produced by the American Pfizer in partnership with the German BioNTech. With that, there are already three substances approved for use in the region. Through another evaluation process, the Argentine Ministry of Health had also released Sputnik V, from the Russian Direct Investment Fund (RDIF).
Immunization in the country started on Tuesday (29/12) with the application of the Russian vaccine. The goal of the local government is to cover 10 million people by February 2021, which corresponds to more than three quarters of the inhabitants who are part of the risk groups in the country according to official projections.
Around the world
Our neighbors were the second country to approve the vaccine produced by AstraZeneca. The United Kingdom was the first to endorse the massive use of the substance in the region’s residents. The application there begins on January 4, according to British Health Secretary Matt Hancock.
India should be another place to start using the Oxford immunizer soon. The process for the emergency authorization of the use of the drug in the country began in early December and, on the last 24, the committee that evaluates the issue received additional data from clinical trials from the Serum Institute of India (SII).
The country is still waiting to send additional data from manufacturers Pfizer and Bharat Biotech for two other vaccines that should be used to immunize the Indian population.
In Latin America, there are three other countries in which vaccination of the population has already begun: Chile, Mexico and Costa Rica. All of them using doses from manufacturers Pfizer-Biontech.
The National Health Surveillance Agency (Anvisa) has not yet approved the use of any vaccine in Brazil. Despite this, the expectation announced by the Minister of Health is that the vaccination process will start by the end of January 2021 with the granting of emergency authorizations.
In the case of the Oxford vaccine, which will be produced here in partnership with the Oswaldo Cruz Foundation (Fiocruz), the process seems to be the most advanced among the immunizers tested in the country so far. According to the president of the Foundation, Nísia Trindade, the sending of documents to Anvisa must be completed by January 15 and local production of the immunizer can begin even before the registration is granted.